$44.25
-0.18-0.41%
At close: -
$44.30
0.050.11%
After Hours: 7:44 PM EDT
Comments
Loading...
Latest CRISPR Therapeutics Stock News | NASDAQ:CRSP | Benzinga
Get the latest news on CRISPR Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on CRISPR Therapeutics performance
Categories: All
Friday, June 20, 2025
Wednesday, June 18, 2025
Tuesday, June 17, 2025
Monday, June 09, 2025
Wednesday, May 21, 2025
Tuesday, May 20, 2025
Monday, May 19, 2025
Friday, May 09, 2025
Thursday, May 08, 2025
Wednesday, May 07, 2025
- CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
- Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
- These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results
- Needham Maintains Buy on CRISPR Therapeutics,...
- Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
- Chardan Capital Maintains Buy on CRISPR Thera...
Tuesday, May 06, 2025
Thursday, May 01, 2025
Wednesday, April 09, 2025
Saturday, April 05, 2025
Wednesday, March 26, 2025
Saturday, March 15, 2025
Wednesday, March 12, 2025
Thursday, February 20, 2025
Wednesday, February 19, 2025
Tuesday, February 18, 2025
Sunday, February 16, 2025
Friday, February 14, 2025
- This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- This Informatica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
- CRISPR Therapeutics shares are trading higher...
- Morgan Stanley Maintains Underweight on CRISP...
- This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
- Evercore ISI Group Upgrades CRISPR Therapeuti...
Thursday, February 13, 2025
Wednesday, February 12, 2025
- Truist Securities Maintains Buy on CRISPR The...
- RBC Capital Maintains Sector Perform on CRISP...
- Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
- CRISPR Therapeutics shares are trading higher...
- Needham Reiterates Buy on CRISPR Therapeutics...
- Barclays Maintains Equal-Weight on CRISPR The...
